Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Primaquine

Research Leaders

7 sponsors active, led by Research Institute for Tropical Medicine, Philippines

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05287893Phase 1Completed

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

NCT05958810Completed

TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018

NCT05958693Completed

TES of Artemether-lumefantrine for Pf in the Philippines in 2015

NCT04222088Completed

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

Showing all 4 trials

Research Network

Common Treatments

  • Primaquine3
  • Artemetherlumefantrine2
  • Pyronaridine1
  • Arthemeterlumefantrine1
  • Chloroquine1

Active Sponsors

  • Research Institute for Tropical Medicine, Philippines3
  • World Health Organization3
  • QIMR Berghofer Medical Research Institute1
  • Swiss BioQuant1
  • Children's Health Queensland Hospital and Health Service1

Top Investigators

Related Conditions

  • Malariafalciparum3
  • Malaria2
  • Parasitemia1
  • Protozoan Infections1
  • Parasitic Disease1

Activity Timeline